scispace - formally typeset
Journal ArticleDOI

Microglial interleukin-1β in the ipsilateral dorsal horn inhibits the development of mirror-image contralateral mechanical allodynia through astrocyte activation in a rat model of inflammatory pain.

Reads0
Chats0
TLDR
Results suggest that spinal IL-1&bgr; derived from activated microglia temporarily suppresses astrocyte activation, which can ultimately prevent the development of contralateral MA under inflammatory conditions, and imply that microglial IL- 1&b gr; plays an important role in regulating the induction of inflammatory MIP.
Abstract
Damage on one side of the body can also result in pain on the contralateral unaffected side, called mirror-image pain (MIP). Currently, the mechanisms responsible for the development of MIP are unknown. In this study, we investigated the involvement of spinal microglia and interleukin-1β (IL-1β) in the development of MIP using a peripheral inflammatory pain model. After unilateral carrageenan injection, mechanical allodynia (MA) in both hind paws and the expression levels of spinal Iba-1, IL-1β, and GFAP were evaluated. Ipsilateral MA was induced beginning at 3 hours after carrageenan injection, whereas contralateral MA showed a delayed onset occurring 5 days after injection. A single intrathecal (i.t.) injection of minocycline, a tetracycline derivative that displays selective inhibition of microglial activation, or an interleukin-1 receptor antagonist (IL-1ra) on the day of carrageenan injection caused an early temporary induction of contralateral MA, whereas repeated i.t. treatment with these drugs from days 0 to 3 resulted in a long-lasting contralateral MA, which was evident in its advanced development. We further showed that IL-1β was localized to microglia and that minocycline inhibited the carrageenan-induced increases in spinal Iba-1 and IL-1β expression. Conversely, minocycline or IL-1ra pretreatment increased GFAP expression as compared with that of control rats. However, i.t. pretreatment with fluorocitrate, an astrocyte inhibitor, restored minocycline- or IL-1ra-induced contralateral MA. These results suggest that spinal IL-1β derived from activated microglia temporarily suppresses astrocyte activation, which can ultimately prevent the development of contralateral MA under inflammatory conditions. These findings imply that microglial IL-1β plays an important role in regulating the induction of inflammatory MIP.

read more

Citations
More filters
Journal ArticleDOI

Microglia induce the transformation of A1/A2 reactive astrocytes via the CXCR7/PI3K/Akt pathway in chronic post-surgical pain

TL;DR: Results indicated that microglia induce the transformation of astrocytes to the A1 phenotype in the spinal cord via downregulation of the CXCR7/PI3K/Akt signaling pathway during CPSP.
Journal ArticleDOI

Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System.

TL;DR: What is currently known with regard to BBB disruption following a hypoxic or inflammatory insult in vivo is looked at and potential mechanisms involved in altering tight junction components at the BBB are discussed.
Journal ArticleDOI

Interleukin‐1beta released by microglia initiates the enhanced glutamatergic activity in the spinal dorsal horn during paclitaxel‐associated acute pain syndrome

TL;DR: The study indicates that IL‐1β is a crucial molecule used by microglia to alter functions in astrocytes and neurons upon activation of TLR4 in the genesis of P‐APS, and targeting the signaling pathways regulating the production and function of IL‐ 1β frommicroglia is a potential avenue for the development of analgesics for the treatment of P-APS.
Journal ArticleDOI

CD200R1 agonist attenuates glial activation, inflammatory reactions, and hypersensitivity immediately after its intrathecal application in a rat neuropathic pain model.

TL;DR: Intrathecal administration of the CD200R1 agonist CD200Fc induces very rapid suppression of neuroinflammatory reactions associated with glial activation and neuropathic pain development, which may constitute a promising and novel therapeutic approach for the treatment of neuropathicPain.
References
More filters
Journal ArticleDOI

Evidence for a central component of post-injury pain hypersensitivity

TL;DR: An animal model is developed where changes occur in the threshold and responsiveness of the flexor reflex following peripheral injury that are analogous to the sensory changes found in man, and shows that it in part arises from changes in the activity of the spinal cord.
Journal ArticleDOI

The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.

TL;DR: Results indicate that NMDA receptors are involved in the induction and maintenance of the central sensitization produced by high threshold primary afferent inputs and have a bearing both on the potential role of NMDA antagonists for pre‐emptive analgesia and for treating established pain states.
Journal ArticleDOI

Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity

TL;DR: Prostaglandin E2 levels in the cerebrospinal fluid are Elevated by finding a widespread induction of Cox-2 expression in spinal cord neurons and in other regions of the CNS, and preventing central prostanoid production by inhibiting the interleukin-1β-mediated induction ofcox-2 in neurons reduces centrally generated inflammatory pain hypersensitivity.
Journal ArticleDOI

Pathological and protective roles of glia in chronic pain

TL;DR: The current understanding of the contribution of glia to pathological pain and neuroprotection is reviewed, and how the protective, anti-inflammatory actions ofglia are being harnessed to develop new drug targets for neuropathic pain control is reviewed.
Journal ArticleDOI

Glial activation: a driving force for pathological pain.

TL;DR: Taken together, these findings suggest a new, dramatically different approach to pain control, as all clinical therapies are focused exclusively on altering neuronal, rather than glial, function.
Related Papers (5)